Clinical trial NCT07021079: Muscle Vibration as a Countermeasure Against Hypoactivity-induced
Official title: Effects of Focal Muscle Vibration as a Countermeasure Against Hypoactivity-induced Neuromuscular Deconditioning
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Vibration Therapy
Healthy Volunteer Study
Hypoactivity
Keywords: hypoactivity
neuromuscular deconditionning
Vibration
Lead sponsor: Centre Hospitalier Universitaire de Saint Etienne
Sponsor class: OTHER
First posted: 2025-06-13
Enrollment: 42
Sex: ALL
Minimum age (years): 19
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Muscle deconditioning, characterized by a loss of muscle mass and strength, is a frequent consequence of prolonged lower limb unloading. Beyond muscle mass loss, reduced neural drive contributes significantly to strength decline, highlighting the need for interventions targeting neuromuscular function during immobilization. Focal muscle vibration (FMV) has shown promise in modulating neuromuscular excitability by activating muscle spindle afferents and inducing cortical adaptations. Chronic use of FMV has been associated with significant strength gains and improved neural command. This makes FMV an effective rehabilitation tool. Its simplicity and non-invasiveness further make it a practical countermeasure.

Detailed description: This study hypothesizes that a 10-day FMV protocol can induce neural adaptations to limit strength loss during unilateral lower limb suspension, offering a novel strategy against neuromuscular function decline.

Eligibility criteria: Inclusion Criteria:

* Men and women.
* Aged 18 to 45 years.
* Body Mass Index (BMI) between 20 and 25 kg/m².
* Engaging in at least 1.5 hours per week of physical activity (e.g., brisk walking, running, swimming, cycling).
* Provided informed consent after receiving detailed information about the study.
* Affiliated with or beneficiaries of a social security system

Exclusion Criteria:

* Chronic cardiovascular, neuromuscular, bone, metabolic, and/or inflammatory disorders.
* Personal history and/or risk factors for thrombosis.
* Use of antidepressant medications.
* Use of neuroactive substances likely to alter corticospinal excitability (e.g., hypnotics, antiepileptics, psychotropics, muscle relaxants) during the study.
* Recent bone or ligament trauma within the past 12 months.
* Inability to perform the physical efforts required for the study.
* Recent participation in a sporting competition or intense, unusual physical activity within the past month.
* Corticosteroid treatment within the past 3 months.
* Any skin lesions at the planned vibrator application site.
* Simultaneous participation in another interventional medical study.
* Pregnant or breastfeeding women.
* Individuals unable to understand the purpose and conditions of the study or unable to provide informed consent.
* Individuals deprived of liberty or under guardianship

Primary outcomes:
measure: Isometric force measurement
timeFrame: Day 1, 7, 14, 28, 33
Secondary outcomes:
measure: Maximum voluntary force measurement
timeFrame: Day 1, 7, 14, 28, 33
measure: Jumping performance measurement
timeFrame: Day 1, 7, 14, 28, 33
measure: Postural balance measurement
timeFrame: Day 1, 7, 14, 28, 33
measure: Neuromuscular fatigue measurement
timeFrame: Day 1, 7, 14, 28, 33
measure: Force-velocity-endurance measurement
timeFrame: Day 1, 7, 14, 28, 33
measure: Voluntary activation level evaluation
timeFrame: Day 1, 7, 14, 28, 33
measure: Cortico-spinal excitability measurement
timeFrame: Day 1, 7, 14, 28, 33
measure: Spinal excitability evaluation
timeFrame: Day 1, 7,14 , 28, 33
measure: Cortical activation of sensorimotor areas measurement
timeFrame: Day 1, 7, 14, 28, 33
measure: Muscle volume measurement
timeFrame: Day 1, 7, 14, 28, 33
measure: Determination of plasma molecular markers of bone and muscle remodeling
timeFrame: Day 1, 7, 14, 28, 33
measure: Determination of plasma molecular markers of bone and muscle remodeling
timeFrame: Day 1, 7, 14, 28, 33
measure: Plasma molecular markers of thrombotic risk evaluation
timeFrame: Day 1, 7, 14, 28, 33
Other outcomes:
Locations:
city: Saint-etienne
country: France
facility: Centre Hospitalier Universitaire
Study officials:
affiliation: CENTRE HOSPITALIER UNIVERSITAIRE SAINT-ETIENNE
name: LEONARD FEASSON, PHD
role: PRINCIPAL_INVESTIGATOR
References: